Stock Movers: Wizz Air, Wise, Bayer (podcast)

Wizz Air shares plummeted 26% after the airline's earnings missed estimates and it withheld guidance due to poor visibility. Conversely, Bayer's stock rose as much as 5.1% following an upgrade by Goldman Sachs from neutral to buy, based on the belief that earnings have bottomed out and litigation/pharma data risks are overstated. In other news, Wise is planning a US stock market listing, which is a blow to the London Stock Exchange.

Analysis

The equity markets showcased significant divergence among specific European names, with Wizz Air Holdings Plc (WIZZ) experiencing a sharp 26% plunge in early trading. This severe downturn was a direct consequence of the discount airline reporting earnings that fell short of analyst estimates and, crucially, its decision to refrain from providing forward guidance due to poor visibility, creating substantial uncertainty around its near-term performance. Conversely, Bayer AG (BAYN) shares surged by as much as 5.1%, driven by an upgrade from Goldman Sachs to 'buy' from 'neutral.' Goldman's revised outlook is predicated on the assessment that Bayer's earnings have likely bottomed out and that perceived risks associated with ongoing litigation and pharmaceutical data are overstated. Separately, the fintech company Wise has announced plans for a U.S. stock market listing, a development viewed as a setback for London's stock market, potentially indicating a trend impacting its attractiveness for new listings.

Key Decisions for Investors

• Investors should approach Wizz Air (WIZZ) with extreme caution given the earnings miss and lack of guidance, and closely monitor for any future operational updates or a reinstatement of financial forecasts before making investment decisions.
• The upgrade for Bayer (BAYN) suggests a more positive outlook, but investors should still diligently track developments in its litigation and pharmaceutical pipeline to confirm that risks are indeed diminishing as suggested by Goldman Sachs.
• Wise's intention to list in the U.S. highlights a potential headwind for the London Stock Exchange; investors with UK market exposure should consider the broader implications of companies opting for overseas listings on the LSE's competitive position.